- Home
- PLUG vs TERN Comparison
PLUG vs TERN Comparison
Compare PLUG & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | TERN |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.8B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLUG | TERN |
|---|---|---|
| Price | $3.79 | $52.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $2.31 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 75.6M | 3.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,919,000.00 | N/A |
| Revenue This Year | $26.67 | N/A |
| Revenue Next Year | $8.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.90 | N/A |
| 52 Week Low | $0.77 | $2.98 |
| 52 Week High | $4.58 | $53.19 |
Technical Indicators
Market Signals| Indicator | PLUG | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 74.51 |
| Support Level | $1.55 | $52.42 |
| Resistance Level | $4.11 | $53.19 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.01 | -0.31 |
| Stochastic Oscillator | 70.28 | 97.30 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.